Long-term Observational Study to Evaluate the DFS and OS of Adjuvant FOLFIRINOX Regimen in Pancreatic Cancer Patients

This observational study tracks how well patients with pancreatic cancer do over the long term after receiving FOLFIRINOX chemotherapy (a combination of four drugs: oxaliplatin, irinotecan, fluorouracil, and leucovorin) as adjuvant (post-surgery) treatment. It records how long patients stay disease-free and overall survival. **You may be eligible if...** - You are 19 or older - You have had surgery for pancreatic cancer (R0 or R1 resection) - You are planning to start FOLFIRINOX chemotherapy after surgery - Your general health is good (ECOG 0 or 1) and your organs can handle chemotherapy **You may NOT be eligible if...** - You have a contraindication to any component of FOLFIRINOX - You are receiving palliative (not curative) therapy - You have previously had a toxic or allergic reaction to FOLFIRINOX Talk to your doctor to see if this trial is right for you.